L-Carnitine Research: What Published Studies Have Investigated

What is L-carnitine?

What is L-carnitine? It is a small quaternary ammonium compound — 3-hydroxy-4-trimethylammoniobutanoate — of formula C₇H₁₅NO₃ and molecular weight about 161.2. It carries a permanent positive charge on its trimethylammonium group and a carboxylate, making it a zwitterion and highly water-soluble. It is also called levocarnitine, and older literature calls it vitamin B_T, a name now considered a misnomer because humans synthesise it.

It is emphatically not a peptide. There is no amino-acid sequence, so the sequence row used on every peptide page here does not apply and has been omitted. L-carnitine is biosynthesised in the human body from lysine and methionine, chiefly in liver and kidney, and is also obtained from diet — red meat is the densest ordinary source. The endogenous pool comprises free L-carnitine plus a range of short-, medium- and long-chain acyl esters, and it is maintained by dietary absorption, biosynthesis and extensive renal tubular reabsorption (Evans and Fornasini, 2003, PMID 12908852).

Stereochemistry matters here more than for most compounds on this site. Only the L enantiomer is biologically active; D-carnitine is not, and racemic material is a different substance from the L form. That is an identity question with an analytical answer, discussed in the verification section.

Discovery and origin in the literature

From muscle extract to a named pathway

Carnitine was first isolated from muscle tissue in the early twentieth century — the name comes from carnis, flesh — and for decades it was a chemical curiosity of unknown function. Its role became clear only when mitochondrial fatty-acid oxidation was worked out in the mid-century: long-chain fatty acyl groups cannot cross the inner mitochondrial membrane as coenzyme A thioesters, and carnitine is the carrier that solves that problem. The resulting three-enzyme system is now taught as the carnitine shuttle.

The genetics that made it a medicine

The second turn in the story is genetic. Human variants in SLC22A5, the gene encoding the high-affinity carnitine transporter OCTN2, cause systemic primary carnitine deficiency — a recognised inherited metabolic disorder in which cells cannot take up carnitine and renal reabsorption fails. El-Hattab and Almannai’s GeneReviews chapter (PMID 22420015) is the standard clinical reference. Levocarnitine is an established treatment for that disorder, and this is where carnitine’s strongest clinical evidence sits: a defined deficiency, a defined molecular cause, and replacement of the missing substance. Longo, Frigeni and Pasquali (2016, PMID 26828774) review the transport and oxidation biology that connects the two.

Reference data

Values from the public chemical record (PubChem CID 10917). Identity and physical form only.

No handling, dilution or reconstitution guidance is given anywhere on this page, and no route or quantity is stated or implied.

Mechanisms researchers have examined

The core biochemistry is settled textbook material, which is unusual for this library and worth stating precisely:

• The carnitine shuttle — carnitine palmitoyltransferase 1 (CPT1) on the outer mitochondrial membrane transfers a long-chain acyl group from coenzyme A to carnitine; carnitine-acylcarnitine translocase moves the acylcarnitine across the inner membrane; CPT2 transfers the acyl group back onto coenzyme A inside the matrix, where β-oxidation proceeds. CPT1 is the rate-limiting step and is itself inhibited by malonyl-CoA, tying the shuttle to the cell’s fatty-acid synthesis state.
• OCTN2-mediated cellular uptake — the SLC22A5 gene product is the high-affinity sodium-dependent transporter that concentrates carnitine in tissue and reabsorbs it in the renal tubule. Loss-of-function variants produce systemic primary carnitine deficiency (Longo 2016; GeneReviews).
• Acyl-group buffering — beyond transport, the free-carnitine/acylcarnitine ratio buffers the mitochondrial acyl-CoA pool. This is why acylcarnitine profiles are a standard analytical readout in metabolic medicine and newborn screening, independent of any supplementation question.
• Saturable oral absorption — Evans and Fornasini (2003) describe absorption after oral administration as occurring partly by carrier-mediated transport, with the pharmacokinetic consequence that oral bioavailability of exogenous carnitine is limited and non-linear. This matters for interpreting any oral study.
• Microbial conversion to TMAO — Koeth and colleagues (2013, Nature Medicine, PMID 23563705) reported that intestinal microbiota metabolise dietary L-carnitine to trimethylamine, which is oxidised to trimethylamine-N-oxide, and that this pathway promoted atherosclerosis in their mouse models. This is a mechanism of the compound’s metabolism, not a claimed effect.

Research findings by area

This section is deliberately selective. The carnitine literature runs to many thousands of papers of wildly varying quality, and citing more of it would communicate less. What follows are areas where systematic reviews or genetic evidence exist.

Primary carnitine deficiency

The clearest evidence base. A defined inherited disorder with a known molecular cause, in which levocarnitine is an established treatment, documented in the GeneReviews clinical chapter (PMID 22420015). Everything else in this section is weaker than this, and the distinction between replacement in a deficiency state and supplementation in a replete one runs through the whole literature.

Haemodialysis and secondary deficiency

Carnitine is small and water-soluble, so it is removed during dialysis, and secondary carnitine depletion in maintenance haemodialysis is a documented phenomenon. Hurot and colleagues (2002, Journal of the American Society of Nephrology, PMID 11856775) conducted a systematic review of L-carnitine supplementation in maintenance haemodialysis patients. This is a defined patient population with a mechanistically plausible depletion — again quite different from general use.

Post-infarction cardiac studies, and the disagreement about them

DiNicolantonio and colleagues (2013, Mayo Clinic Proceedings, PMID 23597877) published a systematic review and meta-analysis of 13 controlled trials (N = 3,629) examining L-carnitine versus placebo or control after acute myocardial infarction, reporting reductions in all-cause mortality, ventricular arrhythmias and angina, with no reduction in heart failure or reinfarction. The authors themselves concluded that further study with large randomised trials in the modern era was warranted — an acknowledgement that much of the pooled data predates contemporary reperfusion practice.

Two points of honesty belong here. First, that meta-analysis attracted published correspondence in the same journal later in 2013, which is part of the record. Second, Shang and colleagues (2014, BMC Cardiovascular Disorders, PMID 25044037) published a separate systematic review and meta-analysis on effective dosing in the same secondary-prevention setting; two independent groups analysing an overlapping evidence base is exactly the situation in which a reader should treat a single headline figure with caution. No confirmatory modern large trial has settled the question.

Healthy subjects, supplementation and TMAO

Sawicka, Renzi and Olek (2020, Journal of the International Society of Sports Nutrition, PMID 32958033) is the most useful single reference for the general-supplementation question, and its title says why: “The bright and the dark sides of L-carnitine supplementation”. From 1,024 retrieved articles the authors found only 11 studies meeting basic quality criteria — healthy subjects, at least 12 weeks, oral, no co-ingested drugs or multi-ingredient supplements. That attrition rate is itself the most informative number in the carnitine literature. The authors reported that supplementation combined with carbohydrate elevated skeletal-muscle total carnitine content, that findings on physical measures varied by population and were not consistent, and that supplementation elevated fasting plasma TMAO, a compound they describe as supposed to be pro-atherogenic. They concluded that further studies on long-term supplementation and cardiovascular effects are needed.

Research models and evidence status

What is well established

The chemistry, the carnitine shuttle, CPT1/CPT2 and translocase function, OCTN2 transport, the pharmacokinetic behaviour of exogenous carnitine, and the genetics and management of primary carnitine deficiency. These rest on decades of independent work and are not in dispute.

What is not established

Almost everything downstream of a defined deficiency state. Whether supplementation changes any meaningful outcome in replete healthy people is not established — Sawicka and colleagues could find only eleven qualifying studies and reported inconsistent findings across them. Whether the post-infarction meta-analytic signal survives a modern, adequately powered randomised trial is not established, and the original authors said so. Whether the elevation in fasting TMAO reported with prolonged supplementation carries any clinical consequence in humans is not established either, in either direction — the mouse atherosclerosis data are mouse data.

The specific hazard with this compound

L-carnitine is the compound in this catalogue most surrounded by low-quality claims, because it is cheap, endogenous, sold as a consumer supplement in many countries, and easy to attach to a story about fat metabolism. The step that story skips is that the carnitine shuttle’s rate-limiting control is CPT1 activity and malonyl-CoA inhibition, not carnitine availability, in tissue that is not carnitine-deficient. Reporting the biochemistry accurately is what makes the gap visible.

This page makes no efficacy, therapeutic, metabolic, weight-related, performance or other use claim of any kind. Every finding above is attributed to the investigators who reported it, in the population they studied. The material is supplied for laboratory research use only — not for human or veterinary use, and not as a dietary supplement.

How to verify this compound yourself

L-carnitine is a small molecule, and its verification differs from the peptide workflow used elsewhere in this library in one respect that dominates all the others:

• Enantiomeric purity is the whole question — L- and D-carnitine have identical molecular formulas, identical molecular weights and identical mass spectra. Ordinary reversed-phase HPLC and mass spectrometry cannot tell them apart. Confirming the L form requires chiral chromatography or optical rotation. A certificate reporting only “99% purity by HPLC” with no chiral method and no specific rotation has not addressed the single most important identity question for this compound.
• Specific optical rotation — a classical, cheap and entirely adequate check for a chiral small molecule, and the value should be on the certificate with the solvent and concentration stated.
• Salt form — carnitine is supplied as the free zwitterion or as salts such as the tartrate or fumarate. These differ in carnitine content per unit mass, so the salt form must be stated for any mass figure to mean anything. This is the small-molecule analogue of the counter-ion question on peptide certificates.
• Water content — the material is hygroscopic, so Karl Fischer water content is a routine and meaningful specification line here in a way it is not for most compounds.
• No sequence, no endotoxin expectation — there is no sequence to confirm, and endotoxin testing is not a standard small-molecule specification; its absence is not a red flag for this compound the way it would be for a peptide intended for cell-culture work.

See how to read a COA for what each certificate line means, and how to verify peptide purity for the peptide workflow this compound departs from. The exact batch received can be checked on the self-serve verify tool.

Research-grade sourcing and verification

L-carnitine is not held in stock. It appears on our sourcing catalogue as available to order — our supplier lists it, we have not bought it, and material of this kind typically takes about two to three weeks to reach us. For laboratory research use only, it is supplied with a per-batch Certificate of Analysis reporting purity and identity confirmation, verifiable at the lot level. It is not supplied as a food, a dietary supplement or a medicine. For other non-peptide metabolic compounds catalogued here with their own separate literatures, see NAD research, AICAR research and 5-Amino-1MQ research. This is sourcing and quality-assurance framing only.

Frequently asked questions

Literature cited

1. Longo N, Frigeni M, Pasquali M. “Carnitine transport and fatty acid oxidation.” Biochimica et Biophysica Acta. 2016;1863(10):2422–2435. PMID 26828774. pubmed.ncbi.nlm.nih.gov/26828774.
2. Evans AM, Fornasini G. “Pharmacokinetics of L-carnitine.” Clinical Pharmacokinetics. 2003;42(11):941–967. PMID 12908852. pubmed.ncbi.nlm.nih.gov/12908852.
3. El-Hattab AW, Almannai M. “Primary Carnitine Deficiency.” GeneReviews. University of Washington, Seattle. PMID 22420015. ncbi.nlm.nih.gov/books/NBK84551.
4. Koeth RA, Wang Z, Levison BS, et al. “Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.” Nature Medicine. 2013;19(5):576–585. PMID 23563705. pubmed.ncbi.nlm.nih.gov/23563705.
5. DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O’Keefe JH. “L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis.” Mayo Clinic Proceedings. 2013;88(6):544–551. PMID 23597877. pubmed.ncbi.nlm.nih.gov/23597877. (Published correspondence followed in Mayo Clin Proc. 2013;88(8):899–901.)
6. Shang R, Sun Z, Li H. “Effective dosing of L-carnitine in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis.” BMC Cardiovascular Disorders. 2014;14:88. PMID 25044037. pubmed.ncbi.nlm.nih.gov/25044037.
7. Hurot JM, Cucherat M, Haugh M, Fouque D. “Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review.” Journal of the American Society of Nephrology. 2002;13(3):708–714. PMID 11856775. pubmed.ncbi.nlm.nih.gov/11856775.
8. Sawicka AK, Renzi G, Olek RA. “The bright and the dark sides of L-carnitine supplementation: a systematic review.” Journal of the International Society of Sports Nutrition. 2020;17(1):49. PMID 32958033. pubmed.ncbi.nlm.nih.gov/32958033.
9. National Center for Biotechnology Information. “PubChem Compound Summary for CID 10917, L-Carnitine.” pubchem.ncbi.nlm.nih.gov/compound/10917 (formula, mass, CAS 541-15-1).